MedTrace Logo

Microvascular Invasion Artificial Intelligence Prediction Via Contrast-enhanced Ultrasound With Explainability

NCT06760494 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2025-01-06

No results posted yet for this study

Summary

An artificial intelligence (AI) model to predict MVI of HCC using contrast-enhanced ultrasound was constructed. This model also has biological explainability. The investigators named it as MAPUSE (MVI AI prediction via contrast-enhanced ultrasound with explainability).

The goal of MAPUSE study is to prospectively test the performance of MAPUSE model on MVI prediction and its biological correlation in different geographical areas of China.

Conditions

  • HCC - Hepatocellular Carcinoma
  • Microvascular Invasion (MVI)

Interventions

DIAGNOSTIC_TEST

the MAPUSE model

Using the MAPUSE model to predict MVI status before surgical resection for HCC patients

Sponsors & Collaborators

  • Chinese Academy of Sciences

    collaborator OTHER_GOV

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Chuan Pang · Chinese PLA General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2024-05-30
Completion
2024-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06760494 on ClinicalTrials.gov